BRCA1 and BRCA2 proteins are well-known HR-mediated repair regulators, and loss of BRCA1/2 function leads to compromised HR-mediated repair capacity in cancer cells [15], so cells presenting this phenotype are highly sensitive to PARP inhibitor treatment. The gene discussed is BRCA1; the disease is cancer.